These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 38235127)
1. Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America. Martinez-Murillo PA; Huttner A; Lemeille S; Medaglini D; Ottenhoff THM; Harandi AM; Didierlaurent AM; Siegrist CA Front Immunol; 2023; 14():1279003. PubMed ID: 38235127 [TBL] [Abstract][Full Text] [Related]
2. Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study. Vianello E; Gonzalez-Dias P; van Veen S; Engele CG; Quinten E; Monath TP; Medaglini D; ; ; Santoro F; Huttner A; Dubey S; Eichberg M; Ndungu FM; Kremsner PG; Essone PN; Agnandji ST; Siegrist CA; Nakaya HI; Ottenhoff THM; Haks MC Lancet Microbe; 2022 Feb; 3(2):e113-e123. PubMed ID: 35544042 [TBL] [Abstract][Full Text] [Related]
3. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP). Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults. Lee AW; Liu K; Lhomme E; Blie J; McCullough J; Onorato MT; Connor L; Simon JK; Dubey S; VanRheenen S; Deutsch J; Owens A; Morgan A; Welebob C; Hyatt D; Nair S; Hamzé B; Guindo O; Sow SO; Beavogui AH; Leigh B; Samai M; Akoo P; Serry-Bangura A; Fleck S; Secka F; Lowe B; Watson-Jones D; Roy C; Hensley LE; Kieh M; Coller BG; Clin Infect Dis; 2024 Apr; 78(4):870-879. PubMed ID: 37967326 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo. Hoff NA; Bratcher A; Kelly JD; Musene K; Kompany JP; Kabamba M; Mbala-Kingebeni P; Dighero-Kemp B; Kocher G; Elliott E; Reilly C; Halbrook M; Ilunga Kebela B; Gadoth A; Ngoie Mwamba G; Tambu M; McIlwain DR; Mukadi P; Hensley LE; Ahuka-Mundeke S; Rutherford GW; Muyembe-Tamfum JJ; Rimoin AW Proc Natl Acad Sci U S A; 2022 Feb; 119(6):. PubMed ID: 35110410 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults. Halperin SA; Das R; Onorato MT; Liu K; Martin J; Grant-Klein RJ; Nichols R; Coller BA; Helmond FA; Simon JK; J Infect Dis; 2019 Aug; 220(7):1127-1135. PubMed ID: 31505665 [TBL] [Abstract][Full Text] [Related]
8. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials. Grais RF; Kennedy SB; Mahon BE; Dubey SA; Grant-Klein RJ; Liu K; Hartzel J; Coller BA; Welebob C; Hanson ME; Simon JK Lancet Microbe; 2021 Feb; 2(2):e70-e78. PubMed ID: 35544244 [TBL] [Abstract][Full Text] [Related]
9. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Huttner A; Combescure C; Grillet S; Haks MC; Quinten E; Modoux C; Agnandji ST; Brosnahan J; Dayer JA; Harandi AM; Kaiser L; Medaglini D; Monath T; ; Roux-Lombard P; Kremsner PG; Ottenhoff TH; Siegrist CA Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404856 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP; Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R; Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361 [TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial. Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239 [TBL] [Abstract][Full Text] [Related]